TORONTO, June 13, 2023— DAMONA Pharmaceuticals, a preclinical biopharmaceutical company focused on the discovery and development of first-in-class small molecules for the treatment and prevention of cognitive symptoms associated with brain disorders and aging, today announced the appointment of John Reilly as the company’s Chief Executive Officer and member of the Board of Directors. Mr.…
read moreDAMONA raises US5.5 Million Seed Stage Financing to Advance Lead Molecule Development to Treat Cognitive Deficits
read moreWe are delighted to announce that the Ontario Brain Institute (OBI) is investing approximately $400,000 CAD in Damona Pharmaceuticals, to provide support to the company developing treatments for cognitive deficits in depression and other brain disorders. DAMONA’s team is excited to engage with OBI, and thank them for their support.
read moreThrough a multicentered collaboration, joining experts from the Centre for Addiction and Mental Health (CAMH) and University Health Network (UHN), Yao and colleagues are presenting this new release, highlighting how depression impairs cortical inhibition and stimulus processing Find Article Cortical processing depends on finely tuned excitatory and inhibitory connections in neuronal microcircuits. Reduced inhibition by…
read moreLIVING WITH DEMENTIA – CTV Your Morning https://www.youtube.com/watch?v=8AVa1frLbyA From CTV Your Morning On September 16th, 2021, CTV Your Morning presented a media piece about memory loss and how CAMH contributes to tackling this issue. It introduces Paul Leah, an individual that had a stroke more than 10 years ago, damaging a quarter of his brain. Paul now lives…
read moreThe human brain, in all its complexity, is nearly impossible to model. Neuroscientists are trying anyway. Illustration by Jeremy Leung The WALRUS, Canadian general-interest magazine published a new piece on May 19th, 2021 about CAMH scientists working towards clarifying the impact of depression on our brain. The piece by writer Simon Lewsen, and beautifully illustrated by…
read moreThe paper was published by Fee et al. in the International Journal of Neuropsychopharmacology. Patients suffering from mood and anxiety disorders often exhibit a deficit in brain inhibition. This deficit in brain inhibition is due do dysfunctional somatostatin (SST) cells, causing mood and cognitive symptoms in patients. Using transgenic mice in which the SST cell…
read moreOur team is proud of being part of the graduating ventures participating in the 2019-2020 Edition of the Creative Destruction Lab (CDL). CDL is a nonprofit organization that delivers an objectives-based program for massively scalable, seed-stage, science- and technology-based companies. Alpha Cog participated in the Health Stream, and received valuable inputs from mentors from September…
read moreCAMH Engage Breakthrough Challenge 2019 awarded to Dr. Thomas Prevot
CAMH Engage Breakthrough Challenge 2019 awarded to Dr. Thomas Prevot http://damonapharma.com/wp-content/uploads/2019/10/BTC-Picture-Thomas.png 1440 780 Etienne Sibille http://0.gravatar.com/avatar/31fca8d52a9ddc2456d689e55abc91df?s=96&d=mm&r=gOn October the 18th, a sold-out crowd of nearly 300 young professionals gathered at Ricarda’s Toronto to award $10,000 as part of the 6th Annual Breakthrough Challenge, a signature event by CAMH Engage in support of mental health research. CAMH Engage is a group of young professionals in Toronto dedicated to reducing the stigma surrounding…
Lifting Brain Fog
Lifting Brain Fog http://damonapharma.com/wp-content/uploads/2019/09/brain-fog.png 1920 800 Etienne Sibille http://0.gravatar.com/avatar/31fca8d52a9ddc2456d689e55abc91df?s=96&d=mm&r=gEffective treatments for cognitive dysfunction, such as declines in memory and other mental faculties often associated with depression or old age, may be within reach, according to Professor Etienne Sibille at the Centre for Addiction and Mental Health (CAMH) and the University of Toronto, Canada.
- 1
- 2